Clinical trials: Cough
Diphtheria, Tetanus
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
The present trial is a follow-up of AL203 study (NCT00343889). Primary Objectives: To describe the antibody persistence at 15 to 18 months of age and the booster effect of a dose of DTaP-HB-PRP~T or Tritanrix-HepB/Hib™ (given…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00534833
- Testing
- DTaP-HB-PRP~T vaccine, Tritanrix-HepB/Hib™, Oral Polio Vaccine
- Where
- 2 sites in Philippines
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cough
Pilot of Zinc Acetate to Improve Chronic Cough
The Pilot of Zinc Acetate to Improve Chronic Cough (ZICO) is a study of 36 patients with chronic refractory cough that will be used to (1) assess if zinc acetate (150 mg/day) will improve patient reported measures of cough, (2)…
- Trial name
- ZICO (NCT03135522)
- Testing
- Zinc Acetate 50 Mg Oral Capsule
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Johns Hopkins University
Smoking Cessation
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
To test the hypothesis that treatment with the inverse agonist nadolol will improve smoking cessation in patients with chronic cough associated with long-term smoking, with or without airflow obstruction, including those with…
- Trial name
- NCT01825122
- Testing
- Nadolol
- Where
- 4 sites in United States
- Volunteers
- 155 people
- Sponsor
- Invion, Inc.
Idiopathic Pulmonary Fibrosis
Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause that results in scarring of the lungs. Cough is reported by 85% of patients with IPF and can be a distressing symptom with significant physical, social and…
- Trial name
- PAciFy Cough (NCT04429516)
- Testing
- Morphine Sulfate
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Idiopathic Pulmonary Fibrosis
Cough Reduction in IPF With Nalbuphine ER
The main purpose of the study is to evaluate the effect of NAL ER on 24-hour cough frequency using objective digital cough monitoring and to assess safety and tolerability of NAL ER.
- Trial name
- CORAL (NCT05964335)
- Testing
- NAL ER
- Where
- 59 sites in Australia, Canada and 8 more
- Volunteers
- 165 people
- Sponsor
- Trevi Therapeutics
Chronic Obstructive Pulmonary Disease
HFNC Effect on BCSS in Patients With COPD
The primary objective of this study is to look for a correlation between the use of high-flow nasal cannula in the outpatient setting in patients with previous chronic obstructive pulmonary disease exacerbation and the change in…
- Trial name
- COPD (NCT02825043)
- Testing
- High-Flow Nasal Cannula
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Oklahoma
Neoplasms, Glandular and Epithelial, Diphtheria
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Data from this study are expected to demonstrate that V501 (Human Papillomavirus (HPV) [Types 6, 11, 16, 18] Recombinant Vaccine) , when administered concomitantly with a combined diphtheria, tetanus, pertussis (Tdap) vaccine and…
- Conditions
- Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus, Whooping Cough
- Trial name
- NCT00325130
- Testing
- Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine, Comparator: Menactra™ (Concomitant), Comparator: Adacel™ (Concomitant)
- Volunteers
- 1,042 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cough
Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough
Primary objective: To assess the efficacy of Levopront® in comparison with Libexin® based on daytime cough resolution rate by Day 8.
- Trial name
- LDP0114 (NCT03837938)
- Testing
- Levopront® syrup 30 mg/5 ml, Libexin®
- Where
- 8 sites in Russia
- Volunteers
- 184 people
- Sponsor
- Dompé Farmaceutici S.p.A
Amyotrophic Lateral Sclerosis
The Use of Airway Clearance Devices in ALS
The investigator is examining the use of one airway clearance medical device compared to the use of two airway clearance medical devices together in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT02682030
- Testing
- High Frequency Chest Compression Device (HFCC), Cough Assist
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Cedars-Sinai Medical Center
Pertussis
Establishing a Controlled Human Infection Model of Bordetella Pertussis
This study aims to establish a Controlled Human Infection Model of Bordetella pertussis by determining a reproducible and safe infectious bacterial dose (challenge inoculum) that achieves colonization and mild symptomatic…
- Trial name
- NCT05136599
- Testing
- Bordetella pertussis D420
- Where
- Canada
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Diphtheria, Tetanus
Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants
This is a study to compare the safety and immune response of a pentavalent DTaP-HB-PRP~T combined vaccine with Tritanrix-HepB/Hib™, when both are given concomitantly with OPV at 6, 10, and 14 weeks of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00348881
- Testing
- DTaP-HB-PRP~T combined vaccine, Tritanrix-HepB/Hib™ vaccine, Oral poliomyelitis vaccine (OPV)
- Where
- 4 sites in Philippines
- Volunteers
- 2,133 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
Primary Objective: To demonstrate that the immune response of the DTaP-IPV-Hep B-PRP~T is non-inferior for all valences to those of the association of PENTAXIM™ and ENGERIX B® PEDIATRICO one month after a three-dose primary…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00831311
- Testing
- DTaP-IPV-HB-PRP~T, DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine
- Where
- Argentina
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Refractory Chronic Cough
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
A randomized, double-blind, placebo-controlled, crossover, dose escalation study to assess the efficacy and tolerability of gefapixant (AF-219; MK-7264) in participants with refractory chronic cough.
- Trial name
- NCT02349425
- Testing
- Gefapixant
- Volunteers
- 59 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Refractory and/or Unexplained Chronic Cough
Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC).
- Trial name
- PAGANINI (NCT04562155)
- Testing
- BAY1817080
- Where
- 99 sites in United States, Argentina and 17 more
- Volunteers
- 310 people
- Sponsor
- Bayer
Chronic Cough
Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)
The purpose of this study is to evaluate the efficacy and safety of gefapixant in participants with recent onset chronic cough (duration >8 weeks after onset of cough symptoms) for <12 months and a diagnosis of refractory or…
- Trial name
- NCT04193202
- Testing
- Gefapixant
- Where
- 91 sites in United States, Canada and 10 more
- Volunteers
- 419 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Diseases, Interstitial
INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
The primary objective of this observational study is to investigate the correlation between changes from baseline at 52 weeks in forced vital capacity (FVC) and changes from baseline at 52 weeks in dyspnea score points or cough…
- Trial name
- INREAL (NCT04702893)
- Testing
- Nintedanib
- Where
- 21 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Pertussis, Whooping Cough
Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine
This study evaluates the safety and immunogenicity of a higher dose formulation of a new live attenuated vaccine, BPZE1, intended to prevent Bordetella pertussis nasopharyngeal colonization and pertussis disease, and investigates…
- Trial name
- NCT02453048
- Testing
- BPZE1
- Where
- Sweden
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Pertussis
Boostrix® Pregnancy Registry
The purpose of this Registry is to detect and describe any abnormal pregnancy outcomes, including teratogenicity, in females intentionally or unintentionally exposed to Boostrix during their pregnancies in the US.
- Trial name
- NCT02096276
- Testing
- Data collection
- Where
- United States
- Volunteers
- 1,517 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with…
- Conditions
- Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05660850
- Testing
- GDC-6599, Mannitol
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Diphtheria, Tetanus
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
This is a follow-up of the primary series vaccination schedule in Study A3L24 (NCT01177722). The objectives are: To describe the antibody persistence to any antigen contained in the investigational DTaP-IPV-Hep B-PRP-T vaccine…
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01444781
- Testing
- DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide, DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide, DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine
- Where
- 2 sites in Colombia, Costa Rica
- Volunteers
- 1,106 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company